U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H35NO2
Molecular Weight 321.4974
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ROSIPTOR

SMILES

[H][C@@]12CCC(=C)[C@@]1(C)CC[C@@]([H])([C@H]2CN)[C@@]3(C)CC[C@H](O)C[C@@H]3CO

InChI

InChIKey=MDEJTPWQNNMAQF-BVMLLJBZSA-N
InChI=1S/C20H35NO2/c1-13-4-5-17-16(11-21)18(7-9-19(13,17)2)20(3)8-6-15(23)10-14(20)12-22/h14-18,22-23H,1,4-12,21H2,2-3H3/t14-,15+,16+,17+,18+,19-,20+/m1/s1

HIDE SMILES / InChI
Rosiptor (AQX-1125) is a once daily, orally administered small molecule being developed by Aquinox Pharmaceuticals for the treatment of asthma, bladder pain syndrome/interstitial cystitis (IC/BPS) and chronic prostatitis/chronic pelvic pain syndrome. AQX-1125 is the only clinical-stage, orally administered, SHIP1 activator. AQX-1125 significantly reduces the late response to allergen challenge, with a trend to reduce airway inflammation. AQX-1125 was safe and well tolerated and merits further investigation in inflammatory disorders. AQX-1125 has been used in trials studying the treatment of COPD, atopic dermatitis, interstitial cystitis, and bladder pain syndrome. However, the development has been discontinued.

Approval Year

PubMed

PubMed

TitleDatePubMed
BioPartnering North America--Spotlight on Canada.
2010 Mar
Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo.
2013 Mar
Current Pharmacologic Approaches in Painful Bladder Research: An Update.
2017 Dec
Patents

Sample Use Guides

AQX-1125 (450 mg daily) was administered orally for 7 days.
Route of Administration: Oral
At 0.1 uM AQX-1125 the inhibition amounted to an average of 34%, while at 10 uM the inhibition amounted to an average of 82% in two independent experiments. Similarly, AQX-1125 exerted a dose-dependent inhibition of Akt phosphorylation in SHIP+/+mouse splenic lymphocytes, with a maximal inhibitory effect at 30 uM amounting to 73% and 82% in T-cells and B cells, respectively as measured by Luminex analysis
Name Type Language
ROSIPTOR
INN   WHO-DD  
INN  
Official Name English
(1S,3S,4R)-4-((3AS,4R,5S,7AS)-4-(AMINOMETHYL)-7A-METHYL-1- METHYLENEOCTAHYDRO -1H - INDEN-5-YL)-3-(HYDROXYMETHYL)-4-METHYLCYCLOHEXANOL
Systematic Name English
AQX-1125
Code English
AQX-1125 FREE BASE
Code English
Rosiptor [WHO-DD]
Common Name English
CYCLOHEXANEMETHANOL, 2-((3AS,4R,5S,7AS)-4-(AMINOMETHYL)OCTAHYDRO-7A-METHYL-1-METHYLENE-1H-INDEN-5-YL)-5-HYDROXY-2-METHYL-, (1S,2R,5S)-
Systematic Name English
7-Amino-17-methylidene-6,7-seco-5α-androstane-3β,6-diol
Systematic Name English
ROSIPTOR [USAN]
Common Name English
rosiptor [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1404
Created by admin on Sat Dec 16 08:39:49 GMT 2023 , Edited by admin on Sat Dec 16 08:39:49 GMT 2023
Code System Code Type Description
CAS
782487-28-9
Created by admin on Sat Dec 16 08:39:49 GMT 2023 , Edited by admin on Sat Dec 16 08:39:49 GMT 2023
PRIMARY
SMS_ID
100000174652
Created by admin on Sat Dec 16 08:39:49 GMT 2023 , Edited by admin on Sat Dec 16 08:39:49 GMT 2023
PRIMARY
DRUG BANK
DB13012
Created by admin on Sat Dec 16 08:39:49 GMT 2023 , Edited by admin on Sat Dec 16 08:39:49 GMT 2023
PRIMARY
INN
10126
Created by admin on Sat Dec 16 08:39:49 GMT 2023 , Edited by admin on Sat Dec 16 08:39:49 GMT 2023
PRIMARY
NCI_THESAURUS
C152258
Created by admin on Sat Dec 16 08:39:49 GMT 2023 , Edited by admin on Sat Dec 16 08:39:49 GMT 2023
PRIMARY
PUBCHEM
76965484
Created by admin on Sat Dec 16 08:39:49 GMT 2023 , Edited by admin on Sat Dec 16 08:39:49 GMT 2023
PRIMARY
USAN
EF-69
Created by admin on Sat Dec 16 08:39:49 GMT 2023 , Edited by admin on Sat Dec 16 08:39:49 GMT 2023
PRIMARY
FDA UNII
6R5034F862
Created by admin on Sat Dec 16 08:39:49 GMT 2023 , Edited by admin on Sat Dec 16 08:39:49 GMT 2023
PRIMARY